Cancer Research and Statistics Foundation (CRSF)

Register for an interesting virtual conference “The Cancer Conclave” happening on 4th February, Saturday between 2 pm to 6.30 pm. Register now to get invited. Register Free: bit.ly/3ZzVMlK #CancerConclave #cancerday #worldcancerday #cancerawareness #cancerfighter #crsf

Phase III Randomized Trial for Use of Docetaxel in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. @VanitaNoronha @Amolpatel_dr @Nandinimenon18 @DrEzraCohen @JCO_ASCO @HHKhar @TataMemorial @DrHaddadRobert ascopubs.org/doi/abs/10.120…

some snapshot of discussion at NMT&PB

1st National Molecular Tumor & precision board met today at 8:00 AM on 26th January 2023. Holistic management with molecular report understanding, Pathway analysis, genetic implications and many more. @HHKhar @HospitalHinduja @VanitaNoronha @SewantiLimaye @Nandinimenon18

सिर और गर्दन के कैंसर में इम्यूनोथेरेपी की व्यवस्था बहुत महंगी है और केवल 1% -3% रोगी ही इसे वहन कर सकते हैं। इस पहले यादृच्छिक अध्ययन में इम्मोथेरेपी की कम खुराक को प्रभावी पाया गया। यह इस कैंसर के लिए एक नई चिकित्सा है जो इम्यूनोथेरेपी की लागत को 95% तक कम करती है

हेड आनी नेक कॅन्सरांत इम्युनोथेरपी पद्दत खूब खर्चीक आसता आनी फकत 1%-3% दुयेंतींक ती परवडटा. ह्या पयल्याच यादीक अभ्यासांत इयुमोथेरपीचो उणो डोस प्रभावी आशिल्ल्याचें दिसून आयलें. ह्या कॅन्सरा खातीर ही एक नवी उपचार पद्दत जी प्रतिरक्षी उपचाराचो खर्च 95% उणो करता.

Cost-effective practice changing therapy 🎉 Low-Dose Immunotherapy in Head & Neck Cancer: A Randomized Study ascopubs.org/doi/abs/10.120… @DrVijayPatil11 @VanitaNoronha @Nandinimenon18 @SachinDhumal999 @TMCcelebrates75 @ACTREC_TMC @DrGunjesh @tmhmedoncalumni @mittualone16

Very Happy 🎉🎉 to share that low dose immunotherapy full text is published in JCO. @JCO_ASCO @VanitaNoronha @Nandinimenon18 @Amolpatel_dr @SuyogCancer @tmhmedoncalumni @oncology_bg Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study . ascopubs.org/doi/abs/10.120…

Need to thank Dr Kumar Prabhash @VanitaNoronha @SachinDhumal999 @Nandinimenon18 @ShwetaJogdhank1 @docameya Dr Nileundu, Dr Suman Kumar , Kavita , Riddhi, @RahulKrRai86 @DrGunjesh and many @tmhmedoncalumni @ACTREC_TMC @TataMemorial

Low dose Nivo worked with triple metronomic Chemo(TMC),It doesn't guarantee it will work alone or with other Chemo combination. IO resistance is mitigated by antiangiogenic and by RTK inhibitors. So MC with antiangiogenic property and erlotinib RTK- Logical and rationale.

Poster on our ongoing study comparing the OMCT versus physicians choice of chemotherapy presentated in @ASCO #ASCO22

We are delighted to inform you that our Phase 3 ongoing trial is selected for poster presentation in @ASCO 2022. #ASCO2022 #oncology

Long term results initial cohort study prompted to do a Doce-RT randomised study in cisplatin eligible. To be presented at #ASCO22 in Head and Neck Oral session. sciencedirect.com/science/articl…

Though overall study was negative. That was probably because we enrolled real world patients . With nearly 1/4 th with poor PS. A population not enrolled in international studies. In PS 0-1 CCNU MBZ seems to work. Looking for collaboration for phase 3. sciencedirect.com/science/articl…

Looking forward to this informative talk by the experts 👏

RMAC study: A randomized study for evaluation of metronomic adjuvant c... sciencedirect.com/science/articl… . @sampada_dessai @drvijayvsh @groundhogcs @nvpatkar @harit_oncochat @Diliphv86 @drmanuprasad @AnantRamaswamy @Avinashp9Dr @VinitSamant @DrVijayPatil11